Do you use biomarkers to improve risk prediction in patients with ADPKD during early disease stages?

Yes. The most important validated prognostic biomarker in early ADPKD is height-adjusted total kidney volume (htTKV), typically measured by MRI and interpreted using the Mayo Imaging Classification. KDIGO recommends htTKV as the preferred imaging biomarker for predicting disease progression and identifying patients at risk for rapid progression who may benefit from disease-modifying therapy such as tolvaptan. While genetic information (e.g., PKD1 truncating variants) and clinical prediction tool...